<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutr J</journal-id><journal-title>Nutrition Journal</journal-title><issn pub-type="epub">1475-2891</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">14594455</article-id><article-id pub-id-type="pmc">240108</article-id><article-id pub-id-type="publisher-id">1475-2891-2-12</article-id><article-id pub-id-type="doi">10.1186/1475-2891-2-12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology [ISRCTN78467674]</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Bartlett</surname><given-names>Hannah</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bartlehe@aston.ac.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Eperjesi</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>F.Eperjesi@aston.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>Neurosciences Research Institute, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK</aff><pub-date pub-type="collection"><year>2003</year></pub-date><pub-date pub-type="epub"><day>10</day><month>10</month><year>2003</year></pub-date><volume>2</volume><fpage>12</fpage><lpage>12</lpage><ext-link ext-link-type="uri" xlink:href="http://www.nutritionj.com/content/2/1/12"/><history><date date-type="received"><day>3</day><month>7</month><year>2003</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2003</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2003 Bartlett and Eperjesi; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><copyright-year>2003</copyright-year><copyright-holder>Bartlett and Eperjesi; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder></permissions><abstract><sec><title>Background</title><p>Age-related macular disease is the leading cause of blind registration in the developed world. One aetiological hypothesis involves oxidation, and the intrinsic vulnerability of the retina to damage via this process. This has prompted interest in the role of antioxidants, particularly the carotenoids lutein and zeaxanthin, in the prevention and treatment of this eye disease.</p></sec><sec sec-type="methods"><title>Methods</title><p>The aim of this randomised controlled trial is to determine the effect of a nutritional supplement containing lutein, vitamins A, C and E, zinc, and copper on measures of visual function in people with and without age-related macular disease. Outcome measures are distance and near visual acuity, contrast sensitivity, colour vision, macular visual field, glare recovery, and fundus photography. Randomisation is achieved via a random number generator, and masking achieved by third party coding of the active and placebo containers. Data collection will take place at nine and 18 months, and statistical analysis will employ Student's t test.</p></sec><sec><title>Discussion</title><p>A paucity of treatment modalities for age-related macular disease has prompted research into the development of prevention strategies. A positive effect on normals may be indicative of a role of nutritional supplementation in preventing or delaying onset of the condition. An observed benefit in the age-related macular disease group may indicate a potential role of supplementation in prevention of progression, or even a degree reversal of the visual effects caused by this condition.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><sec><title>Epidemiology of age-related macular disease</title><p>Age-related macular degeneration is the leading cause of registrable blindness in the developed world [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>], and its prevalence is expected to increase with the anticipated demographic right-shift [<xref ref-type="bibr" rid="B4">4</xref>]. In order to standardise terminology a classification system for age-related macular degeneration has been developed [<xref ref-type="bibr" rid="B5">5</xref>]. Early and late stages of the condition are termed age-related maculopathy (ARM) and age-related macular degeneration (AMD) respectively. The term age-related macular disease will be used to encompass ARM and AMD.</p><p>ARM is most often clinically apparent over the age of 50 years. The main symptom is increasing difficulty with fine detail discrimination. AMD is categorised further in to 'non-neovascular AMD' (also known as dry AMD or geographic atrophy), and 'neovascular AMD' (also known as wet, exudative, or disciform) [<xref ref-type="bibr" rid="B5">5</xref>]. Neovascular AMD refers to the growth of new, weak blood vessels and their subsequent leakage in the macular region of the retina. Non-neovascular AMD is the most common form, and is estimated to be present in 15% of eyes by 80 years of age [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Progression is slow and legal blindness has been estimated to occur between 5 and 10 years [<xref ref-type="bibr" rid="B10">10</xref>]. Neovascular AMD is less common, occurring in 5.2% of the population over 75 years [<xref ref-type="bibr" rid="B2">2</xref>], but accounts for 90% of blind registrations [<xref ref-type="bibr" rid="B11">11</xref>]. Sufferers experience rapid, significant loss of central vision. Neovascular AMD is generally preceded by the non-neovascular form.</p></sec><sec><title>Clinicopathogenesis of age-related macular disease</title><p>The macula is around 5 mm in diameter and is located centrally in the retina. It has a central depressed area, of approximately 1.5 mm diameter, called the fovea. The fovea is located approximately 4 mm temporal from the optic disc. The central floor of the fovea is called the foveola, which has a diameter of 0.35 mm and is the thinnest part of the retina. It contains only cone photoreceptors and their nuclei [<xref ref-type="bibr" rid="B12">12</xref>] (see figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Human fundus.</p></caption><graphic xlink:href="1475-2891-2-12-1"/></fig></sec><sec><title>Aetiology of AMD</title><p>The exact aetiology of AMD is not known, but several hypotheses have been proposed:</p><sec><title>Age-related change to Bruch's membrane and the retinal pigment epithelium (RPE)</title><p>The RPE lies between Bruch's membrane and the sensory retina. It forms the blood-retina barrier and is involved with vitamin A metabolism, transport of metabolites from the choroid to the retina, manufacture of mucopolysaccharides, and breakdown of damaged photoreceptor outer segments. Bruch's membrane separates the RPE from the choriocapillaris, which serves as the main blood supply to the outer retina [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>Increasing age promotes an increased lipid content of Bruch's membrane, and the macula is affected by this process to a greater extent than the periphery [<xref ref-type="bibr" rid="B13">13</xref>]. Consequential changes to the diffusion characteristics of Bruch's membrane may precipitate AMD [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Senescence of RPE cells occurs earlier than in other cell types, such as fibroblasts [<xref ref-type="bibr" rid="B15">15</xref>]. Foveal RPE cells decrease in density and selectively lose their hexagonal shape with age [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. These changes may contribute to the onset of AMD.</p></sec><sec><title>Vascular insufficiency</title><p>Changes to the choroidal and scleral vasculature, and the resulting increase in haemodynamic resistance have been proposed to cause damage to the RPE [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. Foveal choriocapillaris blood flow is reduced with age, but has been shown to be further degraded in AMD patients [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. Laser Doppler flowmetry has been used to establish that choroidal blood volume is reduced via decreased density and diameter of the choriocapillaris [<xref ref-type="bibr" rid="B21">21</xref>].</p></sec><sec><title>Genetics</title><p>An increased risk of AMD has been demonstrated with a positive family history [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>], and this supports the proposed genetic component to development of AMD. It is likely that those with an inherited predisposition for the condition will develop it following exposure to certain risk factors [<xref ref-type="bibr" rid="B24">24</xref>].</p></sec><sec><title>Free radical/ oxidative stress hypothesis</title><p>Reactive oxygen intermediates is an inclusive term used to describe both oxidants and free radical species [<xref ref-type="bibr" rid="B25">25</xref>]. A free radical can be described as 'any atom or molecule that has one or more unpaired electrons' [<xref ref-type="bibr" rid="B26">26</xref>]. Examples include the superoxide anion (O<sup>2-</sup>&#x02022;) and the hydroxyl free radical (OH&#x02022;). Oxidants such as singlet oxygen (<sup>1</sup>0<sub>2</sub>) and hydrogen peroxide (H<sub>2</sub>0<sub>2</sub>) contain paired electrons, but in a reactive state [<xref ref-type="bibr" rid="B27">27</xref>]. It is proposed that many degenerative diseases result from uncontrolled ROI reactions within the body [<xref ref-type="bibr" rid="B28">28</xref>]. A free radical will attempt to achieve stability by gaining electrons from other molecules. These molecules become 'reducing agents' by donating electrons and are damaged by this process. In the retina this damage may lead to the development of age-related macular disease. The retina is particularly susceptible to oxidative stress for several reasons:</p><p>&#x02022; The retina is subject to high levels of radiation, particularly blue light.</p><p>&#x02022; Oxygen consumption by the retina is greater than that of other tissues [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>&#x02022; Photoreceptor outer segments contain a high proportion of polyunsaturated fatty acids, whose double bonds are a rich source of electrons [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>].</p><p>&#x02022; The retina contains photosensitisers, which make cells and tissues sensitive to the influence of irradiation [<xref ref-type="bibr" rid="B32">32</xref>-<xref ref-type="bibr" rid="B34">34</xref>]</p><p>&#x02022; Phagocytosis by the RPE generates ROI [<xref ref-type="bibr" rid="B35">35</xref>].</p><p>The body has several defence mechanisms against free radical damage, including antioxidant enzymes such as superoxide dismutase and catalase, antioxidant vitamins such as vitamins C, E and some carotenoids, and other antioxidant compounds such as metallationein, melanin, and glutathione. For a detailed account of the role of oxidation in the pathogenesis of AMD, see Beatty <italic>et al</italic>. (2000) [<xref ref-type="bibr" rid="B36">36</xref>].</p></sec></sec><sec><title>Antioxidants and AMD</title><p>The lack of treatment options for AMD has prompted a search for possible preventative strategies. The main risk factors for AMD are increasing age [<xref ref-type="bibr" rid="B37">37</xref>-<xref ref-type="bibr" rid="B41">41</xref>], smoking [<xref ref-type="bibr" rid="B42">42</xref>-<xref ref-type="bibr" rid="B44">44</xref>], and family history [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B45">45</xref>-<xref ref-type="bibr" rid="B47">47</xref>]. Proposed risk factors include female gender [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B48">48</xref>], white ethnicity [<xref ref-type="bibr" rid="B49">49</xref>-<xref ref-type="bibr" rid="B51">51</xref>], sunlight exposure [<xref ref-type="bibr" rid="B52">52</xref>,<xref ref-type="bibr" rid="B53">53</xref>], high dietary fat intake [<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>], hypertension [<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B56">56</xref>-<xref ref-type="bibr" rid="B58">58</xref>], and low antioxidant levels [<xref ref-type="bibr" rid="B55">55</xref>,<xref ref-type="bibr" rid="B59">59</xref>]. It follows that the risk of developing ARM and AMD may be reduced by lifestyle changes such as cessation of smoking, minimising sunlight exposure, reducing dietary fat intake, and maintaining antioxidant levels. For a review of randomised controlled trials investigating the role of nutritional supplementation in age-related macular disease, see Bartlett and Eperjesi (2003) [<xref ref-type="bibr" rid="B60">60</xref>].</p></sec><sec><title>The role of lutein and zeaxanthin in prevention and treatment of age-related macular disease</title><p>The isometric carotenoids lutein, zeaxanthin, and meso-zeaxanthin make up the macular pigment (MP) [<xref ref-type="bibr" rid="B61">61</xref>-<xref ref-type="bibr" rid="B63">63</xref>], which appears clinically as a yellow colouration to the macular area. Humans are unable to produce carotenoids but use them in a variety of functions [<xref ref-type="bibr" rid="B64">64</xref>]. Carotenoids are synthesised in plants, algae and bacteria [<xref ref-type="bibr" rid="B65">65</xref>], and the normal Western diet contains 1.3&#x02013;3 mg/day of lutein and zeaxanthin combined [<xref ref-type="bibr" rid="B66">66</xref>,<xref ref-type="bibr" rid="B67">67</xref>].</p><p>Ocular tissues contain several carotenoids, but the retina contains lutein and zeaxanthin exclusively [<xref ref-type="bibr" rid="B68">68</xref>]. Lutein and zeaxanthin are present in rod outer segments, where they would be most needed, and concentrations have been shown to be higher in the macular region than the peripheral retina [<xref ref-type="bibr" rid="B69">69</xref>]. This evidence supports the selective uptake of lutein in the retina and suggests that it plays important role in maintenance of ocular health.</p><p>A 70% reduced risk of AMD has been demonstrated with high (&#x0003e;0.67 &#x003bc;mol/L) versus low (0.25 &#x003bc;mol/L) lutein/zeaxanthin plasma levels [<xref ref-type="bibr" rid="B70">70</xref>]. A study of retinal levels of lutein and zeaxanthin in donor eyes found an 82% lower risk of AMD in retinae among the 25% with highest lutein and zeaxanthin levels compared to the 25% with the lowest levels [<xref ref-type="bibr" rid="B71">71</xref>]. Measurement of macular pigment optical density (MPOD) in healthy eyes showed an age-related decline, and healthy eyes considered to be at risk for AMD had significantly less MP than healthy eyes not at risk [<xref ref-type="bibr" rid="B72">72</xref>]. This evidence suggests that lower plasma and retinal levels of lutein and zeaxanthin present an increased risk of developing AMD.</p><p>Daily supplementation for 140 days with 30 mg of lutein esters produced a seven fold increase in lutein serum levels and a 20&#x02013;40% increase in MPOD [<xref ref-type="bibr" rid="B73">73</xref>]. A 35% increase in lutein serum levels and a 20% increase in MPOD was demonstrated in a study supplementing 11 subjects daily with 11 mg of lutein from 60 g of spinach and 150 g or corn/maize [<xref ref-type="bibr" rid="B74">74</xref>]. Supplementation with 10 mg/day of lutein esters for 12 weeks was shown to increase serum lutein levels by five times and MPOD by approximately 20% [<xref ref-type="bibr" rid="B75">75</xref>]. These studies show that lutein supplementation does increase plasma and retinal lutein levels.</p><p>Lutein and zeaxanthin are believed to protect the retina in two ways. Firstly, they act as blue-light filters. Action spectrum for blue-light induced damage shows a maximum at 400 nm and 450 nm, and this is consistent with the absorption spectrum of macular pigment [<xref ref-type="bibr" rid="B76">76</xref>]. Secondly, they are able to quench free radicals. Energy transfer to them quenches singlet oxygen, and they are also believed to react with peroxy radicals that are involved with lipid peroxidation [<xref ref-type="bibr" rid="B77">77</xref>].</p></sec></sec><sec><title>Objectives</title><p>To determine the effect of 18 months of daily lutein and antioxidant supplementation on measures of visual function in subjects with and without age-related macular disease.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Recruitment</title><p>The study requires recruitment of people with and without age-related macular disease. Recruitment methods employed include sending information to Birmingham optometrists, ophthalmologists, and a specialist centre for rehabilitation of people with sight loss, an editorial in the Birmingham Evening Mail, recruitment e-mails sent to the Royal National Institute for the Blind (RNIB) and all staff and students at Aston University and Aston Science Park. A project website has also been developed at <ext-link ext-link-type="uri" xlink:href="http://www.aston.ac.uk/lhs/research/nri/opo/amd"/>. Data collection takes place in a standard consulting room at Aston University. Enrolment, randomisation, and data collection are carried out by HB. HB and FE are masked to group assignment. HB is a research optometrist and FE is an optometrist and lecturer at Aston University, Birmingham, UK.</p></sec><sec><title>Inclusion/exclusion criteria</title><p>For inclusion participants a) have to provide written informed consent, b) have to be available for three visits to Aston University, c) have to present with no ocular pathology in one eye, or no ocular pathology other than dry AMD in one eye. A cataract grading system consisting of grades one, two and three for each of cortical, nuclear, and posterior subcapsular cataracts has been developed. Participants presenting with lens opacities precluding fundus photography are excluded. Throughout the trial period, progression of any type of cataract to the successive grade will require the participant to withdraw.</p><p>Exclusion criteria include type I and II diabetes because vitamin E has been shown to affect glucose tolerance [<xref ref-type="bibr" rid="B78">78</xref>-<xref ref-type="bibr" rid="B82">82</xref>] and diabetic retinopathy may confound the results. Those taking Warfarin medication are excluded as zinc may decrease its absorption and activity [<xref ref-type="bibr" rid="B83">83</xref>], as are those who use nutritional supplements that potentially raise vitamin and mineral intake above safe limits. The most recent guidelines for upper limits of nutritional supplementation are set out in the UK Food Standards Agency report [<xref ref-type="bibr" rid="B84">84</xref>]. Neovascular AMD and other ocular disease that could potentially interfere with the results are excluded.</p></sec><sec><title>Masking</title><p>The study formulation and placebo tablets have been produced by Quest Vitamins Ltd, Aston Science Park, Birmingham, B7 4AP, and are identical in external and internal appearance, and taste. The manufacturer has allocated distinguishing symbols, &#x003bc; and &#x003bb;. The tablets are packaged in identical, sealed, white containers; the only difference being the symbol on the label. Investigators and participants do not know which symbol represents the placebo tablets, and which represents the active formulation.</p></sec><sec><title>Intervention</title><p>The study formulation contains the following:</p><p>Lutein 6 mg</p><p>Vitamin A 750 &#x003bc;g</p><p>Vitamin C 250 mg</p><p>Vitamin E 34 mg</p><p>Zinc 10 mg</p><p>Copper 0.5 mg</p><p>Participants in both groups are instructed to take one tablet, at the same time every day, with food.</p></sec><sec><title>Randomisation</title><p>The random number generator function in Microsoft Excel is being used to allocate participants to &#x003bc; and &#x003bb; groups. Odd numbers allocate to the &#x003bc; group.</p></sec><sec><title>Baseline data</title><p>On application, participants complete a health questionnaire, a food frequency questionnaire, and a food diary. The health questionnaire provides information about general health, medication, nutritional supplementation, smoking history, ocular health, and time spent living abroad. The food questionnaire and diary ask for information about diet for analysis using Foodbase 2000 software (The Institute of Brain Chemistry and Human Nutrition, London N7 8DB).</p></sec><sec><title>Outcome measures</title><p>The investigation of several measures of visual function is required, as age-related macular disease can produce varying signs and symptoms.</p><sec><title>Visual acuity</title><p>Distance and near visual acuity (VA) measured using Bailey-Lovie logMAR charts. LogMAR charts have 5 letters and 0.1 log MAR progression per line. The advantage of using these charts is that they provide an equal-interval scale, and there are five letters per line. Standard Snellen charts do not provide a linear scale and have a decreasing number of letters per line as the letter size increases.</p></sec><sec><title>Contrast sensitivity</title><p>Contrast sensitivity (CS) is measured using a Pelli-Robson chart (Clement Clarke International, Edinburgh Way, Harlow, Essex, CM20 2TT, UK) and provides additional information about vision. The Pelli-Robson chart determines the contrast required to read large letters and is designed to test mid- to low-spatial frequencies. Some people may have normal visual acuity, but reduced contrast sensitivity at low spatial frequencies, particularly if they suffer from ocular pathologies such as age-related macular disease.</p></sec><sec><title>Colour vision</title><p>Colour vision measured using the PV-16 quantitative colour vision test (Precision Vision Inc, 944 First Street, La Salle, IL, 61301, USA). Macular disease can cause a deficiency in blue-yellow colour vision as the short-wavelength photoreceptors are concentrated around the fovea.</p></sec><sec><title>Macular Mapping Test</title><p>Macular Mapping (MM) test (The Smith-Kettlewell Research Institute, 2318 Fillmore Street, San Francisco, CA, 94115, USA) was developed to map visual defects caused by macular disease. It was developed by MacKeben and Colenbrander [<xref ref-type="bibr" rid="B85">85</xref>] and differs from conventional field analysis in that the stimuli are single letters rather than spots of light. This is a novel piece of equipment and each participant is given a practice run to eliminate learning effects. At the end of the test a single figure score is presented.</p></sec><sec><title>Glare recovery</title><p>Eger Macular Stressometer (EMS) (Gulden Ophthalmics, Elkins Park, PA 19027) is used to assess glare recovery, also known as photostress recovery time (PSRT). This is the time taken for the regeneration of photopigments in bleached photoreceptors to a level that allows resolution of, for example, a letter at near. Resynthesis of the photopigments is dependent upon the integrity of the photoreceptors and RPE [<xref ref-type="bibr" rid="B86">86</xref>]; it follows that the PSRT may be extended in those with diseases affecting these structures. This is a novel piece of equipment and each participant is given a practice run to eliminate learning effects.</p></sec><sec><title>Fundus photography</title><p>Fundus photographs of the macular will be assessed using colour and edge analysis software.</p></sec></sec><sec><title>Follow up</title><p>Data collection will take place at baseline, nine, and 18 months.</p></sec><sec><title>Analyses</title><p>For each outcome measure the change between baseline, nine month, and 18 month values will be calculated. A Student's t test will be used to determine whether the means of these values differ at the 5% significance level between the placebo and active formulation results for age-related macular disease participants, and normal participants, after differences in age, gender and diet have been taken into account.</p></sec><sec><title>Power</title><p>From initial data collection we have calculated the treatment group sizes required in order to have 80% power at the 5% significance level for VA, CS, MM test, and the EMS. These values suggest that a total of 63 normal, and 96 age-related macular disease participants are required.</p></sec><sec><title>Ethical approval</title><p>The study has been approved by the Aston University Human Sciences Ethical Committee. The tenets of the Declaration of Helsinki are being followed [<xref ref-type="bibr" rid="B87">87</xref>].</p></sec></sec><sec><title>Discussion</title><p>Randomised masked trials differ from observational studies in that they have the ability to demonstrate causality. The influence of confounding variables is reduced by random assignment of participants to intervention groups, and masking reduces the influence of investigator bias. There is evidence for selective deposition of lutein in the retina, increase of retinal and serum levels of lutein with supplementation, and an increased risk of age-related macular disease with reduced retinal lutein levels. This randomised controlled trial will provide further information regarding the effect of lutein and antioxidant supplementation on specific measures of visual function in people with and without age-related macular disease. The current paucity of treatment modalities for this condition has prompted research into the development of prevention strategies. A positive effect of the supplementation on normals may be indicative of its potential role in prevention or delaying the onset of age-related macular disease. This may be of particular importance for those with a positive family history, or exposure to other risk factors. A positive effect in age-related macular disease affected eyes may suggest a role of nutritional supplementation in prevention of progression of the disease, or even in reversal of symptoms.</p></sec><sec><title>Competing interests</title><p>None declared.</p></sec></body><back><ack><sec><title>Acknowledgments</title><p>This research is funded by the College of Optometrists, UK.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>JR</given-names></name></person-group><article-title>Causes of blindness and partial sight in England and Wales 1990-1991</article-title><source>Studies on medical and population subjects</source><year>1995</year><volume>57</volume><publisher-name>London, HMSO</publisher-name></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BEK</given-names></name><name><surname>Linton</surname><given-names>KLP</given-names></name></person-group><article-title>Prevalence of Age-Related Maculopathy - the Beaver Dam Eye Study</article-title><source>Ophthalmology</source><year>1992</year><volume>99</volume><fpage>933</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">1630784</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>W</given-names></name><name><surname>Attebo</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name></person-group><article-title>Prevalence of Age-Related Maculopathy in Australia - the Blue Mountains Eye Study</article-title><source>Ophthalmology</source><year>1995</year><volume>102</volume><fpage>1450</fpage><lpage>1460</lpage><pub-id pub-id-type="pmid">9097791</pub-id></citation></ref><ref id="B4"><citation citation-type="other"><person-group person-group-type="author"><collab>United Nations</collab></person-group><article-title>The world population prospects: the 2002 revision. www.un.org/esa/population/publications/wpp2000/highlights.pdf</article-title><year>2002</year></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>AEC</given-names></name><name><surname>Bressler</surname><given-names>NM</given-names></name><name><surname>Bressler</surname><given-names>SB</given-names></name><name><surname>Chisholm</surname><given-names>IH</given-names></name><name><surname>Coscas</surname><given-names>G</given-names></name><name><surname>Davis</surname><given-names>MD</given-names></name><name><surname>Dejong</surname><given-names>Ptvm</given-names></name><name><surname>Klaver</surname><given-names>CCW</given-names></name><name><surname>Klein</surname><given-names>BEK</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Sarks</surname><given-names>JP</given-names></name><name><surname>Sarks</surname><given-names>SH</given-names></name><name><surname>Sourbane</surname><given-names>G</given-names></name><name><surname>Taylor</surname><given-names>HR</given-names></name><name><surname>Vingerling</surname><given-names>JR</given-names></name></person-group><article-title>An International Classification and Grading System for Age- Related Maculopathy and Age-Related Macular Degeneration</article-title><source>Survey of Ophthalmology</source><year>1995</year><volume>39</volume><fpage>367</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">7604360</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bressler</surname><given-names>NM</given-names></name><name><surname>Bressler</surname><given-names>SB</given-names></name><name><surname>Fine</surname><given-names>SL</given-names></name></person-group><article-title>Age-related macular degeneration</article-title><source>Survey of Ophthalmology</source><year>1988</year><volume>32</volume><fpage>375</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">2457955</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bressler</surname><given-names>NM</given-names></name><name><surname>Bressler</surname><given-names>SB</given-names></name><name><surname>Fine</surname><given-names>SL</given-names></name></person-group><article-title>Subfoveal neovascular membranes in senile macular degeneration: relationship between membrane size and visual prognosis</article-title><source>Retina</source><year>1983</year><volume>3</volume><fpage>7</fpage><lpage>11</lpage></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>RP</given-names></name></person-group><article-title>Age-related macular degeneration</article-title><source>Ophthalmology</source><year>1986</year><volume>93</volume><fpage>969</fpage><lpage>971</lpage><pub-id pub-id-type="pmid">2429244</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tso</surname><given-names>MOM</given-names></name></person-group><article-title>Pathogenic factors of aging macular degeneration</article-title><source>Ophthalmology</source><year>1985</year><volume>92</volume><fpage>628</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">2409505</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>JJ</given-names></name><name><surname>Sarks</surname><given-names>SH</given-names></name></person-group><article-title>Extracts from "Clinical evidence" - Age related macular degeneration</article-title><source>Br Med J</source><year>2000</year><volume>321</volume><fpage>741</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">10999909</pub-id><pub-id pub-id-type="doi">10.1136/bmj.321.7263.741</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chopdar</surname><given-names>A</given-names></name><name><surname>Chakravarthy</surname><given-names>U</given-names></name><name><surname>Verma</surname><given-names>D</given-names></name></person-group><article-title>Age-related macular degeneration</article-title><source>British Medical Journal</source><year>2003</year><volume>326</volume><fpage>485</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">12609947</pub-id><pub-id pub-id-type="doi">10.1136/bmj.326.7387.485</pub-id></citation></ref><ref id="B12"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kanski</surname><given-names>JJ</given-names></name></person-group><source>Clinical Ophthalmology</source><year>1994</year><edition>Third</edition><publisher-name>Oxford, Butterworth-Heineman</publisher-name></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holz</surname><given-names>FG.et.al</given-names></name></person-group><article-title>Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane</article-title><source>Archives of Ophthalmology</source><year>1994</year><volume>112</volume><fpage>402</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">8129668</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ambati</surname><given-names>J</given-names></name><name><surname>Ambati</surname><given-names>BK</given-names></name><name><surname>Yoo</surname><given-names>SH</given-names></name><name><surname>Ianchulev</surname><given-names>S</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name></person-group><article-title>Age-Related Macular Degeneration: Etiology,Pathogenesis, and Therapeutic Strategies</article-title><source>Survey of Ophthalmology</source><year>2003</year><volume>48</volume><fpage>257</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">12745003</pub-id><pub-id pub-id-type="doi">10.1016/S0039-6257(03)00030-4</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rawes</surname><given-names>V</given-names></name><name><surname>Kipling</surname><given-names>D</given-names></name><name><surname>Kill</surname><given-names>IR</given-names></name><name><surname>Faragher</surname><given-names>RG</given-names></name></person-group><article-title>The kinetics of senescence in retinal pigment epithelial cells: a test for the telomere hypothesis of ageing?</article-title><source>Biochemistry</source><year>1997</year><volume>62</volume><fpage>1291</fpage><lpage>1295</lpage><pub-id pub-id-type="pmid">9467853</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorey</surname><given-names>CK</given-names></name><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Ebenstein</surname><given-names>D</given-names></name></person-group><article-title>Cell loss in the aging retina. Relationship to lipofuscin accumulation and macular degeneration</article-title><source>Invest Ophthalmol Vis Sci</source><year>1989</year><volume>30</volume><fpage>1691</fpage><lpage>1699</lpage><pub-id pub-id-type="pmid">2759786</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watzke</surname><given-names>RC</given-names></name><name><surname>Soldevilla</surname><given-names>JD</given-names></name><name><surname>Trune</surname><given-names>DR</given-names></name></person-group><article-title>Morphometric analysis of human retinal pigment epithelium: correlation with age and location</article-title><source>Current Eye Research</source><year>1993</year><volume>12</volume><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">8449024</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>E</given-names></name></person-group><article-title>A hemodynamic model of the pathogenesis of age-related macular degeneration</article-title><source>American Journal of Ophthalmology</source><year>1997</year><volume>124</volume><fpage>677</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">9372722</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>E</given-names></name></person-group><article-title>The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration</article-title><source>American Journal of Ophthalmology</source><year>2000</year><volume>130</volume><fpage>658</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">11078846</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9394(00)00643-7</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grunwald</surname><given-names>JE</given-names></name><name><surname>Hariprasad</surname><given-names>SM</given-names></name><name><surname>DuPont</surname><given-names>J</given-names></name></person-group><article-title>Effect of aging on foveolar choroidal circulation</article-title><source>Archives of Ophthalmology</source><year>1998</year><volume>116</volume><fpage>150</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">9488265</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grunwald</surname><given-names>JE</given-names></name><name><surname>Hariprasad</surname><given-names>SM</given-names></name><name><surname>DuPont</surname><given-names>J</given-names></name></person-group><article-title>Foveolar choroidal blood flow in age-related macular degeneration</article-title><source>Investigative Ophthalmological Vision Science</source><year>1998</year><volume>39</volume><fpage>385</fpage><lpage>390</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hyman</surname><given-names>LG</given-names></name><name><surname>Lilienfeld</surname><given-names>AM</given-names></name><name><surname>Ferris</surname><given-names>FL</given-names></name><name><surname>Fine</surname><given-names>SL</given-names></name></person-group><article-title>Senile Macular Degeneration - a Case-Control Study</article-title><source>Am J Epidemiol</source><year>1983</year><volume>118</volume><fpage>213</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">6881127</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>W</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name></person-group><article-title>Family history and age-related maculopathy: the Blue Mountains Eye Study</article-title><source>Archives of Ophthalmology</source><year>1998</year><volume>26</volume><fpage>203</fpage><lpage>206</lpage></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>A</given-names></name></person-group><article-title>Age-related macular disease</article-title><source>Br J Ophthalmol</source><year>1996</year><volume>80</volume><fpage>2</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">8664224</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>RC</given-names></name><name><surname>Richer</surname><given-names>SP</given-names></name><name><surname>Bode</surname><given-names>AM</given-names></name></person-group><article-title>Ocular Oxidants and Antioxidant Protection</article-title><source>Proceedings of the Society for Experimental Biology and Medicine</source><year>1998</year><volume>217</volume><fpage>397</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">9521086</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Southorn</surname><given-names>PA</given-names></name><name><surname>Powis</surname><given-names>G</given-names></name></person-group><article-title>Free radicals in medicine I. Chemical nature and biological reactions</article-title><source>Mayo Clinical Procedures</source><year>1988</year><volume>63</volume><fpage>381</fpage><lpage>389</lpage></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halliwell</surname><given-names>B</given-names></name></person-group><article-title>Reactive oxygen species in living systems: source, biochemistry and role in human disease</article-title><source>Am J Med</source><year>1991</year><volume>91 (Supp)</volume><fpage>14</fpage><lpage>22</lpage></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Florence</surname><given-names>TM</given-names></name></person-group><article-title>Ther role of free radicals in disease (review)</article-title><source>Australian and New Zealand Journal of Ophthalmology</source><year>1995</year><volume>23</volume><fpage>3</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7619452</pub-id></citation></ref><ref id="B29"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Sickel</surname><given-names>W</given-names></name></person-group><person-group person-group-type="editor"><name><surname>FuortesMGF</surname></name></person-group><article-title>Retinal metabolism in dark and light</article-title><source>Handbook of sensory physiology</source><year>1972</year><publisher-name>Berlin, Springer-Verlag</publisher-name><fpage>667</fpage><lpage>727</lpage></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bazan</surname><given-names>NG</given-names></name></person-group><article-title>The metabolism of omega-3 polyunsaturated fatty acids in the eye: the possible role of docosahexaenoic acid and docosanoids in retinal physiology and ocular pathology</article-title><source>Progress in Clinical and Biological Research</source><year>1989</year><volume>312</volume><fpage>95</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">2529559</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>WL</given-names></name><name><surname>Farnsworth</surname><given-names>CC</given-names></name><name><surname>Dratz</surname><given-names>EA</given-names></name></person-group><article-title>A reinvestigation of the fatty acid content of bovine, rat and frog retinal rod outer segments</article-title><source>Experimental Eye Research</source><year>1979</year><volume>28</volume><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">446567</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delmelle</surname><given-names>M</given-names></name></person-group><article-title>Retinal sensitized photodynamic damage to liposomes</article-title><source>Photochemistry and Photobiology</source><year>1978</year><volume>28</volume><fpage>357</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">704692</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaillard</surname><given-names>ER</given-names></name><name><surname>Atherton</surname><given-names>SJ</given-names></name><name><surname>Eldred</surname><given-names>G</given-names></name><name><surname>Dillon</surname><given-names>J</given-names></name></person-group><article-title>Photophysical studies on human retinal lipofuscin</article-title><source>Photochemistry and Photobiology</source><year>1995</year><volume>61</volume><fpage>448</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">7770505</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rozanowska</surname><given-names>M</given-names></name><name><surname>Jarvis-Evans</surname><given-names>J</given-names></name><name><surname>Korytowski</surname><given-names>W</given-names></name></person-group><article-title>Blue light-induced reactivity of retinal pigment. In vitro generation of oxygen-reactive species</article-title><source>Journal of Biological Chemistry</source><year>1995</year><volume>270</volume><fpage>18825</fpage><lpage>18830</lpage><pub-id pub-id-type="pmid">7642534</pub-id><pub-id pub-id-type="doi">10.1074/jbc.270.32.18825</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tate</surname><given-names>DJ Jr</given-names></name><name><surname>Miceli</surname><given-names>MV</given-names></name><name><surname>Newsome</surname><given-names>DA</given-names></name></person-group><article-title>Phagocytosis and H202 induce catalase and metallothionein gene expression in human retinal pigment epithelial cells</article-title><source>Invest Ophthalmol Vis Sci</source><year>1995</year><volume>36</volume><fpage>1271</fpage><lpage>1279</lpage><pub-id pub-id-type="pmid">7775104</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beatty</surname><given-names>S</given-names></name><name><surname>Koh</surname><given-names>HH</given-names></name><name><surname>Henson</surname><given-names>D</given-names></name><name><surname>Boulton</surname><given-names>M</given-names></name></person-group><article-title>The role of oxidative stress in the pathogenesis of age-related macular degeneration</article-title><source>Surv Ophthalmol</source><year>2000</year><volume>45</volume><fpage>115</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">11033038</pub-id><pub-id pub-id-type="doi">10.1016/S0039-6257(00)00140-5</pub-id></citation></ref><ref id="B37"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>HA</given-names></name><name><surname>Moorhead</surname><given-names>HB</given-names></name></person-group><source>Statistics on blindness in the Model Reporting Area 1969-1970.</source><year>1973</year><publisher-name>Washington. DC, US DHEW</publisher-name></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>J</given-names></name><name><surname>Flowerdew</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>E</given-names></name><name><surname>Brody</surname><given-names>JA</given-names></name><name><surname>Tso</surname><given-names>MOM</given-names></name></person-group><article-title>Factors Associated with Age-Related Macular Degeneration - an Analysis of Data from the 1st National-Health and Nutrition Examination Survey</article-title><source>Am J Epidemiol</source><year>1988</year><volume>128</volume><fpage>700</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">3421236</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>BS</given-names></name><name><surname>Bird</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>West</surname><given-names>SK</given-names></name></person-group><article-title>Epidemiology of age-related macular degeneration</article-title><source>Mol Vis</source><year>1999</year><volume>5</volume><fpage>U7</fpage><lpage>U10</lpage></citation></ref><ref id="B40"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Berger JW; Fine SL; Maguire MG</surname></name></person-group><article-title>Epidemiology</article-title><source>Age-Related Macular Degeneration</source><year>1999</year><publisher-name>Philadelphia, Mosby</publisher-name><fpage>31</fpage><lpage>55</lpage></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>W</given-names></name><name><surname>Assink</surname><given-names>J</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Klaver</surname><given-names>CCW</given-names></name><name><surname>Klein</surname><given-names>BEK</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Jensen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>de Jong</surname><given-names>Ptvm</given-names></name></person-group><article-title>Risk factors for age related macular degeneration - Pooled findings from three continents</article-title><source>Ophthalmology</source><year>2001</year><volume>108</volume><fpage>697</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">11297486</pub-id><pub-id pub-id-type="doi">10.1016/S0161-6420(00)00580-7</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><collab>Tamakoshi</collab><collab>Akiko</collab><collab>Yuzawa</collab><collab>Mitsuko</collab><collab>Matsui</collab><collab>Mizuo</collab></person-group><article-title>Smoking and neovascular form of age-related macular degeneration in late middle aged males: findings from a case-control study in Japan</article-title><source>British Journal of Ophthalmology</source><year>1997</year><volume>81</volume><fpage>901</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">9486034</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seddon</surname><given-names>JM</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Speizer</surname><given-names>FE</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name></person-group><article-title>A prospective study of cigarette smoking and age-related macular degeneration in women</article-title><source>JAMA</source><year>1996</year><volume>276</volume></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>RL</given-names></name></person-group><article-title>Smoking, platelets and thrombosis</article-title><source>Nature</source><year>1972</year><volume>236</volume><fpage>450</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">4555360</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heiba</surname><given-names>IM,et.al</given-names></name></person-group><article-title>Sibling correlations and segregation analysis of age-related maculopathy: the Beaver Dam Eye Study</article-title><source>Genetic Epidemiology</source><year>1994</year><volume>11</volume><fpage>51</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">8013888</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klaver</surname><given-names>CCW</given-names></name><collab>Smith</collab><collab>Smith</collab></person-group><article-title>Familial aggregation of age-related macular degeneration in the Rotterdam Study (abstract)</article-title><source>Investigative Opthalmological Visual Science</source><year>1997</year><volume>38</volume><fpage>S967</fpage></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klaver</surname><given-names>CCW</given-names></name><name><surname>Wolfs</surname><given-names>RCW</given-names></name><name><surname>Assink</surname><given-names>JJM</given-names></name></person-group><article-title>Genetic Risk of Age-Related Maculopathy.  Population-Based Familial Aggregation Study</article-title><source>Archives of Ophthalmology</source><year>1998</year><volume>116</volume><fpage>1646</fpage><lpage>1651</lpage><pub-id pub-id-type="pmid">9869796</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>HA</given-names></name><collab>smith</collab><collab>jones.</collab></person-group><article-title>The Framingon Eye Study. 1. Outline and major prevalence findings</article-title><source>American Journal of Epidemiology</source><year>1977</year><volume>106</volume><fpage>17</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">879158</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schachat</surname><given-names>AP</given-names></name><name><surname>Hyman</surname><given-names>L</given-names></name><name><surname>Leske</surname><given-names>MC</given-names></name><name><surname>Connell</surname><given-names>AMS</given-names></name><name><surname>Wu</surname><given-names>SY</given-names></name></person-group><article-title>Features of Age-Related Macular Degeneration in a Black- Population</article-title><source>Arch Ophthalmol</source><year>1995</year><volume>113</volume><fpage>728</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">7786213</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>DS</given-names></name><name><surname>Katz</surname><given-names>J</given-names></name><name><surname>Bressler</surname><given-names>NM</given-names></name><name><surname>Rahmani</surname><given-names>B</given-names></name><name><surname>Tielsch</surname><given-names>JM</given-names></name></person-group><article-title>Racial differences in the prevalence of age-related macular degeneration - The Baltimore eye survey</article-title><source>Ophthalmology</source><year>1999</year><volume>106</volume><fpage>1049</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">10366070</pub-id><pub-id pub-id-type="doi">10.1016/S0161-6420(99)90267-1</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jampol</surname><given-names>LM</given-names></name><name><surname>Tielsch</surname><given-names>JM</given-names></name></person-group><article-title>Race, Macular Degeneration, and the Macular Photocoagulation Study</article-title><source>Archives of Ophthalmology</source><year>1992</year><volume>110</volume><fpage>1699</fpage><lpage>1700</lpage><pub-id pub-id-type="pmid">1281402</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cruickshanks</surname><given-names>KJ</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BEK</given-names></name><name><surname>Nondahl</surname><given-names>DM</given-names></name></person-group><article-title>Sunlight and the 5-year incidence of early age-related maculopathy - The Beaver Dam Eye Study</article-title><source>Arch Ophthalmol</source><year>2001</year><volume>119</volume><fpage>246</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">11176987</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delcourt</surname><given-names>C</given-names></name><name><surname>Carriere</surname><given-names>I</given-names></name><name><surname>Ponton-Sanchez</surname><given-names>A</given-names></name></person-group><article-title>Light Exposure and the Risk of Age-Related Macular Degeneration: The POLA Study</article-title><source>Archives of Ophthalmology</source><year>2001</year><volume>119</volume><fpage>1463</fpage><lpage>1468</lpage><pub-id pub-id-type="pmid">11594945</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mares-Perlman</surname><given-names>JA.et.al</given-names></name></person-group><article-title>Dietary fat and age-related maculopathy</article-title><source>Archives of Ophthalmology</source><year>1995</year><volume>113</volume><fpage>743</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">7786215</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yannuzzi</surname><given-names>LA</given-names></name><name><surname>Sorenson</surname><given-names>JA</given-names></name><name><surname>Sobel</surname><given-names>RS</given-names></name><name><surname>Daly</surname><given-names>JR</given-names></name><name><surname>Derosa</surname><given-names>JT</given-names></name><name><surname>Seddon</surname><given-names>JM</given-names></name><name><surname>Gragoudas</surname><given-names>ES</given-names></name><name><surname>Puliafito</surname><given-names>CA</given-names></name><name><surname>Gelles</surname><given-names>E</given-names></name><name><surname>Gonet</surname><given-names>R</given-names></name><name><surname>Burton</surname><given-names>TC</given-names></name><name><surname>Culver</surname><given-names>J</given-names></name><name><surname>Metzger</surname><given-names>K</given-names></name><name><surname>Kalbfleisch</surname><given-names>N</given-names></name><name><surname>Zarling</surname><given-names>D</given-names></name><name><surname>Farber</surname><given-names>MD</given-names></name><name><surname>Blair</surname><given-names>N</given-names></name><name><surname>Stelmack</surname><given-names>T</given-names></name><name><surname>Axelrod</surname><given-names>A</given-names></name><name><surname>Waitr</surname><given-names>SE</given-names></name><name><surname>Cross</surname><given-names>A</given-names></name><name><surname>Rolnick</surname><given-names>C</given-names></name><name><surname>Flom</surname><given-names>T</given-names></name><name><surname>Haller</surname><given-names>J</given-names></name><name><surname>Pusin</surname><given-names>S</given-names></name><name><surname>Cassel</surname><given-names>G</given-names></name><name><surname>Applegate</surname><given-names>CA</given-names></name><name><surname>Seigel</surname><given-names>D</given-names></name><name><surname>Sperduto</surname><given-names>RD</given-names></name><name><surname>Hiller</surname><given-names>R</given-names></name><name><surname>Mowery</surname><given-names>R</given-names></name><name><surname>Chew</surname><given-names>E</given-names></name><name><surname>Tamboli</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>DT</given-names></name><name><surname>Sowell</surname><given-names>AL</given-names></name><name><surname>Gunter</surname><given-names>EW</given-names></name><name><surname>Dunn</surname><given-names>M</given-names></name><name><surname>Shamban</surname><given-names>K</given-names></name><name><surname>Lento</surname><given-names>D</given-names></name><name><surname>Alexander</surname><given-names>JA</given-names></name><name><surname>Phillips</surname><given-names>DA</given-names></name></person-group><article-title>Risk-Factors for Neovascular Age-Related Macular Degeneration</article-title><source>Arch Ophthalmol</source><year>1992</year><volume>110</volume><fpage>1701</fpage><lpage>1708</lpage><pub-id pub-id-type="pmid">1281403</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hyman</surname><given-names>L</given-names></name><collab>Smith</collab><collab>Smith</collab></person-group><article-title>Risk factors for age-related maculopathy</article-title><source>Investigative Ophthalmological Vision Science</source><year>1992</year><volume>33</volume><fpage>801</fpage></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>W</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Leeder</surname><given-names>SR.et.al</given-names></name></person-group><article-title>Plasma Fibrinogen Levels, Other Cardiovascular Risk Factors, and Age-Related Maculopathy</article-title><source>Archives of Ophthalmology</source><year>1998</year><volume>116</volume><fpage>583</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">9596493</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><collab>The Age-Related Eye Disease Study Research Group</collab></person-group><article-title>Risk factors associated with age-related macular degeneration - A case-control study in the Age-Related Eye Disease Study: Age- Related Eye Disease Study report number 3</article-title><source>Ophthalmology</source><year>2000</year><volume>107</volume><fpage>2224</fpage><lpage>2232</lpage><pub-id pub-id-type="pmid">11097601</pub-id><pub-id pub-id-type="doi">10.1016/S0161-6420(00)00409-7</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richer</surname><given-names>S</given-names></name></person-group><article-title>Multicenter ophthalmic and nutritional age-related macular degeneration study part 2: antioxidant intervention and conclusions</article-title><source>J Am Optom Assoc</source><year>1996</year><volume>67</volume><fpage>30</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">8825017</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>H</given-names></name><name><surname>Eperjesi</surname><given-names>F</given-names></name></person-group><article-title>Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials</article-title><source>Ophthalmic and Physiological Optics</source><year>2003</year><volume>23</volume><fpage>383</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">12950886</pub-id><pub-id pub-id-type="doi">10.1046/j.1475-1313.2003.00130.x</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Handelman</surname><given-names>GJ</given-names></name><name><surname>Dratz</surname><given-names>EA</given-names></name><name><surname>Reay</surname><given-names>CC</given-names></name></person-group><article-title>Carotenoids in the human macula and the whole retina</article-title><source>Invest Ophthalmol Vis Sci</source><year>1988</year><volume>29</volume><fpage>850</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">3372162</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>RA;</given-names></name><name><surname>Landrum</surname><given-names>JT;</given-names></name><name><surname>Tarsis</surname><given-names>SL;</given-names></name></person-group><article-title>Preliminary identification of the human macular pigment</article-title><source>Vision Res</source><year>1985</year><volume>25</volume><fpage>1531</fpage><lpage>1535</lpage><pub-id pub-id-type="pmid">3832576</pub-id><pub-id pub-id-type="doi">10.1016/0042-6989(85)90123-3</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khachik</surname><given-names>F</given-names></name><name><surname>Bernstein</surname><given-names>PS</given-names></name><name><surname>Garland</surname><given-names>DL</given-names></name></person-group><article-title>Identification of lutein and zeaxanthin oxidation products in human and monkey retinas</article-title><source>Invest Ophthalmol Vis Sci</source><year>1997</year><volume>38</volume><fpage>1802</fpage><lpage>1811</lpage><pub-id pub-id-type="pmid">9286269</pub-id></citation></ref><ref id="B64"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Isler</surname><given-names>O</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Basel</surname></name></person-group><source>Carotenoids</source><year>1971</year><publisher-name>Birkhauser-Verlag</publisher-name></citation></ref><ref id="B65"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>TW</given-names></name></person-group><person-group person-group-type="editor"><name><surname>PackerL</surname></name></person-group><source>Methods in Enzymology</source><year>1992</year><volume>213</volume><publisher-name>New York, Academic Press</publisher-name><fpage>167</fpage><lpage>172</lpage></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nebeling</surname><given-names>LC</given-names></name><name><surname>Forman</surname><given-names>MR</given-names></name><name><surname>Graubard</surname><given-names>BI</given-names></name><name><surname>Snyder</surname><given-names>RA</given-names></name></person-group><article-title>Changes in carotenoid intake in the United States. The 1987 and 1992 National Health Interview Surveys</article-title><source>Journal of the American Dietetic Association</source><year>1997</year><volume>97</volume><fpage>991</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">9284877</pub-id><pub-id pub-id-type="doi">10.1016/S0002-8223(97)00239-3</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nebeling</surname><given-names>LC</given-names></name><name><surname>Forman</surname><given-names>MR;</given-names></name><name><surname>Graubard</surname><given-names>BI</given-names></name><name><surname>Snyder</surname><given-names>RA</given-names></name></person-group><article-title>The Impact of Lifestyle Characterisitcs on Carotenoid Intake in the United States: The 1987 National Health Interview Survey</article-title><source>American Journal of Public Health</source><year>1997</year><volume>87</volume><fpage>268</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">9103108</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>PS</given-names></name><name><surname>Khachik</surname><given-names>F</given-names></name><name><surname>Carvalho</surname><given-names>LS</given-names></name><name><surname>Muir</surname><given-names>GJ</given-names></name><name><surname>Zhao</surname><given-names>DY</given-names></name><name><surname>Katz</surname><given-names>NB</given-names></name></person-group><article-title>Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye</article-title><source>Experimental Eye Research</source><year>2001</year><volume>72</volume><fpage>215</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">11180970</pub-id><pub-id pub-id-type="doi">10.1006/exer.2000.0954</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rapp</surname><given-names>LM</given-names></name><name><surname>Maple</surname><given-names>SS</given-names></name><name><surname>Choi</surname><given-names>JH</given-names></name></person-group><article-title>Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina</article-title><source>Investigative Ophthalmology &#x00026; Visual Science</source><year>2000</year><volume>41</volume><fpage>1200</fpage><lpage>1209</lpage><pub-id pub-id-type="pmid">10752961</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><collab>EDCCS Group</collab></person-group><article-title>Antioxidant status and neovascular age-related macular degeneration. The Eye Disease Case Control Study Group.</article-title><source>Archives of Ophthalmology</source><year>1993</year><volume>111</volume><fpage>104</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">7678730</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>RA</given-names></name><name><surname>Landrum</surname><given-names>JT</given-names></name><name><surname>Mayne</surname><given-names>ST</given-names></name><name><surname>Gomez</surname><given-names>CM</given-names></name><name><surname>Tibor</surname><given-names>SE</given-names></name><name><surname>Twaroska</surname><given-names>EE</given-names></name></person-group><article-title>Macular pigment in donor eyes with and without AMD: A case-control study</article-title><source>Invest Ophthalmol Vis Sci</source><year>2001</year><volume>42</volume><fpage>235</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">11133874</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beatty</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>IJ</given-names></name><name><surname>Henson</surname><given-names>DB</given-names></name><name><surname>Carden</surname><given-names>D</given-names></name><name><surname>Koh</surname><given-names>H</given-names></name><name><surname>Boulton</surname><given-names>ME</given-names></name></person-group><article-title>Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population</article-title><source>Investigative Ophthalmology &#x00026; Visual Science</source><year>2001</year><volume>42</volume><fpage>439</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">11157880</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landrum</surname><given-names>JT</given-names></name><name><surname>Bone</surname><given-names>RA</given-names></name><name><surname>Joa</surname><given-names>H</given-names></name><name><surname>Kilburn</surname><given-names>MD</given-names></name><name><surname>Moore</surname><given-names>LL</given-names></name><name><surname>Sprague</surname><given-names>KE</given-names></name></person-group><article-title>A one year study of the macular pigment: the effect of 140 days of a lutein supplement</article-title><source>Experimental Eye Research</source><year>1997</year><volume>65</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">9237865</pub-id><pub-id pub-id-type="doi">10.1006/exer.1997.0309</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammond</surname><given-names>B R, Jr</given-names></name><name><surname>Johnson</surname><given-names>EJ</given-names></name><name><surname>Russell</surname><given-names>RM</given-names></name><name><surname>Krinsky</surname><given-names>NI</given-names></name><name><surname>Yeum</surname><given-names>KJ</given-names></name><name><surname>Edwards</surname><given-names>RB</given-names></name><name><surname>Snodderly</surname><given-names>DM</given-names></name></person-group><article-title>Dietary modification of human macular pigment density</article-title><source>Investigative Ophthalmology &#x00026; Visual Science</source><year>1997</year><volume>38</volume><fpage>1795</fpage><lpage>1801</lpage><pub-id pub-id-type="pmid">9286268</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berendschot</surname><given-names>Ttjm</given-names></name><name><surname>Goldbohm</surname><given-names>RA</given-names></name><name><surname>Klopping</surname><given-names>WAA</given-names></name><name><surname>van de Kraats</surname><given-names>J</given-names></name><name><surname>van Norel</surname><given-names>J</given-names></name><name><surname>van Norren</surname><given-names>D</given-names></name></person-group><article-title>Influence of lutein supplementation on macular pigment, assessed with two objective techniques</article-title><source>Invest Ophthalmol Vis Sci</source><year>2000</year><volume>41</volume><fpage>3322</fpage><lpage>3326</lpage><pub-id pub-id-type="pmid">11006220</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ham</surname><given-names>WT Jr</given-names></name><name><surname>Mueller</surname><given-names>HA</given-names></name><name><surname>Ruffolo</surname><given-names>JJ Jr</given-names></name></person-group><article-title>Basic mechanisms underlying the production of photochemical lesions in the mammalian retina</article-title><source>Curr Eye Res</source><year>1984</year><volume>3</volume><fpage>165</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">6690219</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landrum</surname><given-names>JT</given-names></name><name><surname>Bone</surname><given-names>RA</given-names></name></person-group><article-title>Lutein, zeaxanthin, and the macular pigment</article-title><source>Archives of Biochemistry and Biophysics</source><year>2001</year><volume>385</volume><fpage>28</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11361022</pub-id><pub-id pub-id-type="doi">10.1006/abbi.2000.2171</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bierenbaum</surname><given-names>ML</given-names></name><name><surname>Noonan</surname><given-names>FJ</given-names></name><name><surname>Machlin</surname><given-names>LJ</given-names></name></person-group><article-title>The effect of supplemental vitamin E on serum parameters in diabetics, post coronary and normal subjects.</article-title><source>Nutr Rep Int</source><year>1985</year><volume>31</volume><fpage>1171</fpage><lpage>1180</lpage></citation></ref><ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paolisso</surname><given-names>G</given-names></name><name><surname>D&#x02019;Amore</surname><given-names>A</given-names></name><name><surname>Giugliano</surname><given-names>D</given-names></name></person-group><article-title>Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin dependent diabetic patients.</article-title><source>Am J Clin Nutr</source><year>1993</year><volume>57</volume><fpage>650</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">8480681</pub-id></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paolisso</surname><given-names>G</given-names></name><name><surname>D&#x02019;Amore</surname><given-names>A</given-names></name><name><surname>Galzerano</surname><given-names>D</given-names></name></person-group><article-title>Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients.</article-title><source>Diabetes Care</source><year>1993</year><volume>16</volume><fpage>1433</fpage><lpage>1437</lpage><pub-id pub-id-type="pmid">8299431</pub-id></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>T&#x000fc;t&#x000fc;nc&#x000fc;</surname><given-names>NB</given-names></name><name><surname>Bayraktar</surname><given-names>M</given-names></name><name><surname>Varli</surname><given-names>K</given-names></name></person-group><article-title>Reversal of defective nerve condition with vitamin E supplementation in type 2 diabetes</article-title><source>Diabetes Care</source><year>1998</year><volume>21</volume><fpage>1915</fpage><lpage>1918</lpage><pub-id pub-id-type="pmid">9802743</pub-id></citation></ref><ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skrha</surname><given-names>J</given-names></name><name><surname>Sindelka</surname><given-names>G</given-names></name><name><surname>Kvasnicka</surname><given-names>J</given-names></name><name><surname>Hilgertova</surname><given-names>J</given-names></name></person-group><article-title>Insulin action and fibrinolysis influenced by vitamin E in obese type 2 diabetes mellitus</article-title><source>Diabetes Res Clin Pract</source><year>1999</year><volume>44</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">10414937</pub-id><pub-id pub-id-type="doi">10.1016/S0168-8227(99)00010-8</pub-id></citation></ref><ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>JT</given-names></name></person-group><article-title>The pharmacokinetic and pharmacodynamic interactions of foods and drugs</article-title><source>Topics in Clinical Nutrition</source><year>1991</year><volume>6</volume><fpage>14</fpage><lpage>33</lpage></citation></ref><ref id="B84"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Minerals</surname><given-names>Expert Group on Vitamins and</given-names></name></person-group><source>Safe Upper Limits for Vitamins and Minerals</source><year>2003</year><publisher-name>www.foodstandards.gov.uk/multimedia/pdfs/vitamins2003.pdf, Food Standard Agency</publisher-name></citation></ref><ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacKeben</surname><given-names>M</given-names></name><name><surname>Colenbrander</surname><given-names>A</given-names></name></person-group><article-title>The assessment of residual vision in patients with maculopathies. Non-invasive assessment of the visual system</article-title><source>Technical Digest</source><year>1993</year><volume>3</volume><fpage>274</fpage><lpage>277</lpage></citation></ref><ref id="B86"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Brindley</surname><given-names>GS</given-names></name></person-group><source>Physiology of the retina and visual pathways</source><year>1970</year><publisher-name>Baltimore, Williams and Wilkins</publisher-name></citation></ref><ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><collab>World Medical Association</collab></person-group><article-title>Declaration of Helsinki</article-title><source>Journal of the Americal Medical Society</source><year>1997</year><volume>277</volume><fpage>925</fpage><lpage>926</lpage></citation></ref></ref-list></back></article>


